Showing 1871-1880 of 2494 results for "".
- Pfizer, BioNTech Begin Phase 2/3 Coronavirus Vaccine Studyhttps://modernod.com/news/pfizer-biontech-pick-bnt162b2-to-advance-into-phase-2-3-coronavirus-vaccine-study/2478084/Pfizer and partner BioNTech said they have decided to advance the nucleoside-modified mRNA vaccine candidate BNT162b2 into phase 2/3 testing. The vaccine, to be trialed at the 30-mcg dose as part of a two-dose regimen, encodes for an optimized SARS-CoV-2 full-length spike glycoprotein, which the
- New Dates Announced for BMC Virtual Spring Symposiumhttps://modernod.com/news/new-dates-announced-for-bmc-virtual-spring-symposium/2477658/Bryn Mawr Communications (BMC) has announced that its first virtual educational initiative, the BMC Virtual Spring Symposium, will now be held on May 29-30. The BMC Virtual Spring Symposium is designed to enable discussion, engagement, and live Q&A for members of the vision community w
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- Iveric bio Appoints Guangping Gao, PhD, Internationally Recognized Gene Therapy Pioneer as Chief Strategist, Gene Therapyhttps://modernod.com/news/iveric-bio-appoints-guangping-gao-phd-internationally-recognized-gene-therapy-pioneer-as-chief-strategist-gene-therapy/2477122/Iveric bio announced the appointment of Guangping Gao, PhD, as Chief Strategist, Gene Therapy. Dr. Gao brings more than 30 years of scientific research experience in gene-based treatments. As one of the world’s leading gene therapy experts, Dr. Gao’s highly distinguished career includes major con
- Aerpio Pharmaceuticals Announces Review of Strategic Alternativeshttps://modernod.com/news/aerpio-pharmaceuticals-announces-review-of-strategic-alternatives/2477023/Aerpio Pharmaceuticals announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the company’s clinical assets and cash resources, which amounted to $48.2 million as of June 30, 2019. The Boar
- Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476963/On the eve of World Sight Day, Orbis International is celebrating achievements of the eye health community over the past two decades, and warns of a projected global tripling in demand for eye care over the next 30 years. 2020 is a critical year for Orbis International and other leaders in
- On World Sight Day, Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/on-world-sight-day-orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476936/Today, Orbis International commemorates World Sight Day by celebrating achievements of the eye health community over the past two decades, and warning of a projected global tripling of blindness over the next 30 years. Next year is a critical year for Orbis International and other leaders
- Nicox Provides Business Update and Upcoming Milestoneshttps://modernod.com/news/nicox-provides-business-update-and-upcoming-milestones/2476887/Nicox SA reported the financial results for Nicox and its subsidiaries for the 6 months ending June 30, 2019 and provided an update on its activities as well as key upcoming milestones. “This is a compelling and potentially transformative time for Nicox, as we make strong progress in our g
- Staar Surgical Announces Strategic Alliance Agreement with Asian Eye Institutehttps://modernod.com/news/staar-surgical-announces-strategic-alliance-agreement-with-asian-eye-institute/2476850/Staar Surgical Company announced that it has entered a strategic alliance with Asian Eye Institute, an eye care group with nine locations in the Philippines. Asian Eye Institute was founded in 2001 and has 18 medical doctors, two specialist optometrists, and more than 30 staff optometrists on sta
- Kowa Submits IND Application to the FDA to Begin Phase 2 Study of Ripasudil Hydrochloride Hydratehttps://modernod.com/news/kowas-submits-ind-application-to-the-fda-to-begin-phase-2-study-of-ripasudil-hydrochloride-hydrate/2476842/Kowa, which has been developing Ripasudil Hydrochloride Hydrate, a Rho kinase inhibitor, for the indication of corneal endothelial diseases, submitted an investigational new drug (IND) application to the FDA on August 30, 2019 in order to commence a phase 2 clinical